Capricor Therapeutics (NASDAQ:CAPR) Receives Buy Rating from HC Wainwright

Capricor Therapeutics (NASDAQ:CAPR)‘s stock had its “buy” rating reaffirmed by equities researchers at HC Wainwright in a research note issued on Monday,Benzinga reports. They presently have a $77.00 target price on the biotechnology company’s stock. HC Wainwright’s price target suggests a potential upside of 481.79% from the stock’s previous close.

Capricor Therapeutics Stock Performance

Capricor Therapeutics stock traded up $0.01 during midday trading on Monday, hitting $13.24. 477,640 shares of the company’s stock were exchanged, compared to its average volume of 1,359,141. The stock has a 50-day moving average price of $14.18 and a two-hundred day moving average price of $14.41. Capricor Therapeutics has a 52-week low of $3.52 and a 52-week high of $23.40. The company has a market cap of $601.80 million, a P/E ratio of -12.47 and a beta of 4.10.

Hedge Funds Weigh In On Capricor Therapeutics

Hedge funds and other institutional investors have recently modified their holdings of the company. Magnus Financial Group LLC bought a new stake in shares of Capricor Therapeutics in the 4th quarter valued at about $276,000. State Street Corp lifted its stake in shares of Capricor Therapeutics by 27.8% in the 3rd quarter. State Street Corp now owns 512,313 shares of the biotechnology company’s stock valued at $7,792,000 after acquiring an additional 111,291 shares during the last quarter. JPMorgan Chase & Co. lifted its stake in shares of Capricor Therapeutics by 419.5% in the 3rd quarter. JPMorgan Chase & Co. now owns 56,199 shares of the biotechnology company’s stock valued at $855,000 after acquiring an additional 45,381 shares during the last quarter. Point72 Asset Management L.P. bought a new stake in shares of Capricor Therapeutics in the 3rd quarter valued at about $3,806,000. Finally, Black Diamond Financial LLC bought a new position in Capricor Therapeutics during the 4th quarter valued at approximately $3,833,000. 21.68% of the stock is currently owned by hedge funds and other institutional investors.

About Capricor Therapeutics

Capricor Therapeutics, Inc (NASDAQ:CAPR) is a clinical-stage biotechnology company focused on the discovery, development and commercialization of first-in-class biological therapeutics for the treatment of rare disorders. Capricor’s lead candidate, CAP-1002, is an allogeneic cell therapy that is currently in clinical development for the treatment of Duchenne muscular dystrophy.